Abstracts tagged "autoantibodies and SMN"

Abstract Number: 403 • 2019 ACR/ARP Annual Meeting
Single-specificity Anti-SMN Autoantibodies Are Associated with a Novel Scleromyositis Overlap Syndrome
Alexandra Baril-Dionne ¹, Océane Landon-Cardinal², Alain Meyer ³, Josiane Bourre-Tessier ¹, Yves Troyanov ⁴, Anne-Marie Mansour ⁵, Farah Zarka ⁵, Jean-Paul Makhzoum ⁶, Jessica Nehme ⁵, Eric Rich ¹, Jean-Richard Goulet ¹, Tamara Grodzicky ¹, Isabelle Richard ⁷, Marie Hudson ⁸, Valérie Leclair ⁹, Ira Targoff ¹⁰, Minoru Satoh ¹¹, Marvin Fritzler ¹² and Jean-Luc Senecal ¹, ¹Centre hospitalier de l'Universite de Montreal, Montreal, QC, Canada, ²Division of Rheumatology, Centre hospitalier de l'Université de Montréal; Department of Medicine, Université de Montréal, Montreal, QC, Canada, ³Centre de Reference des Maladies Autoimmunes Rares, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ⁴Division of Rheumatology, Department of Medicine, Hôpital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁵Hôpital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁶Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁷CISSS AT Rouyn-Noranda, Rouyn-Noranda, QC, Canada, ⁸Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada, ⁹Division of Rheumatology, Department of Medicine, Jewish General Hospital; Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Montreal, QC, Canada, ¹⁰University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹¹Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹²Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Autoantibodies (aAbs) to proteins comprising the survival of motor neuron (SMN) macromolecular complex have not been thoroughly studied. Only two publications described clinical associations…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].